english.prescrire.org > Spotlight > Archives : 2013 > In the May issue of Prescrire International: Panitumumab (Vectibix°) as adjunctive therapy for metastatic colorectal cancer

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2013 : 1 | 30 | 60

In the May issue of Prescrire International: Panitumumab (Vectibix°) as adjunctive therapy for metastatic colorectal cancer

FREE DOWNLOAD This text from the New Products section of the May issue of Prescrire International concludes that panitumumab has no place in either first- or second-line treatment of metastatic colorectal cancer.
Full text available for free download.

Summary

  • There is no evidence that panitumumab prolongs overall survival in patients with metastatic colorectal cancer.
     
  • However, this drug provokes additional, frequent and potentially life-threatening adverse effects.
     
  • It is better to avoid using panitumumab altogether and to stick with standard protocols.

Full text available for free download.

 ©Prescrire 1 May 2013

"Panitumumab adjunctive therapy" Prescrire Int 2013; 22 (138): 120. (Pdf, free)

Download the full review
Pdf, free